Finance

Lists
SNW:ETR
Sanofi SA
71,62 €
+0,93%
(+0,66) 1D
9-окт., 17:35:58 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for SNW...
Open
72,10 €
High
72,10 €
Low
71,52 €
Mkt. cap
86,19 млд
Avg. vol.
14,08 миң
Volume
8,61 миң
P/E ratio
21,97
52-wk high
90,75 €
52-wk low
69,77 €
EPS
3,26 €
Shares outstanding
1,25 млд
No. of employees
75 миң
Open
72,10 €
High
72,10 €
Low
71,52 €
Mkt. cap
86,19 млд
Avg. vol.
14,08 миң
Volume
8,61 миң
P/E ratio
21,97
52-wk high
90,75 €
52-wk low
69,77 €
EPS
3,26 €
Shares outstanding
1,25 млд
No. of employees
75 миң
News stories
From web sources and news partners
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOBelén Garijo | Paul Hudson
Employees74,8 миң
Founded1973
HeadquartersПариж, Иль-де-Франция, Франция
SectorPharmaceutical industry
Websitesanofi.com
Last report
2026-ж., 30-июл.
Fiscal period
Q2 2026
- / 1,90 €
Revenue / Est. (EUR)
12,30 млд / 10,89 млд
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
13,17 млд
12,20 млд
11,24 млд
12,30 млд
Cost of goods sold
3,41 млд
3,63 млд
3,06 млд
2,89 млд
Cost of revenue
3,41 млд
3,63 млд
3,06 млд
2,89 млд
Research and development expenses
1,83 млд
2,29 млд
1,75 млд
2,23 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,29 млд
2,82 млд
2,33 млд
2,49 млд
Operating expense
5,97 млд
6,84 млд
5,94 млд
6,82 млд
Total operating expenses
9,39 млд
10,46 млд
9,00 млд
9,71 млд
Operating income
3,78 млд
1,74 млд
2,25 млд
2,59 млд
Other non operating income
-
122,00 млн
-40,00 млн
-91,00 млн
EBT including unusual items
3,51 млд
-1,16 млд
2,01 млд
828,00 млн
EBT excluding unusual items
3,67 млд
1,70 млд
2,14 млд
2,40 млд
Income tax expense
680,00 млн
-348,00 млн
420,00 млн
451,00 млн
Effective tax rate
19,38%
30,13%
20,85%
54,47%
Other operating expenses
1,39 млд
1,19 млд
1,33 млд
1,55 млд
Net income
2,80 млд
-801,00 млн
1,61 млд
343,00 млн
Net profit margin
21,28%
-6,56%
14,35%
2,79%
Earnings per share
-
1,53
1,88
-
Interest and investment income
114,00 млн
79,00 млн
60,00 млн
64,00 млн
Interest expense
-227,00 млн
-
-138,00 млн
-153,00 млн
Net interest expenses
-113,00 млн
79,00 млн
-78,00 млн
-89,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
4,20 млд
3,49 млд
2,78 млд
3,83 млд
Gain or loss from assets sale
266,00 млн
-79,00 млн
-
-9,00 млн
AI content may include mistakes. Learn more
Google колдонмолору